MedNexus
2021年 · 第101卷第15期
MedNexus
- 全部
- 述评
- 临床研究
- 新技术新方法
- 经验交流
- 疑难病例析评
- 病例报告
- 综述
- 文献速览
Although asthma patients can be effectively controlled through drug treatment, there are still 5% to 10% of severe asthma patients who are uncontrolled or partially controlled, and are more likely to have recurrent attacks and possibly life-threatening deterioration than mild asthma patients, seriously damaging the quality of life and bringing a heavy economic burden to individuals and society. Bronchial thermoplasty (BT) aims to reduce airway smooth muscle and improve asthma control. To investigate the safety and efficacy of BT in patients with symptomatic severe asthma, the study will use fluticasone (750 mg/d) or an equivalent dose of long-acting beta2Thirty-two adult asthmatic patients who were treated with receptor agonists and other drugs, including prednisone tablets at 30 mg/d or less, but still had symptoms, were randomly divided into BT and control groups, 15 in BT and 17 in control. Following treatment, the subject entered a 16-week steroid stable phase (Week 6 to Week 22), a 14-week steroid discontinuation phase (Week 22 to Week 36) and a 16-week steroid reduction phase (Week 36 to Week 52). The results showed that BT caused a transient aggravation of asthma symptoms. During the treatment period, 7 of 4 subjects in the BT group were hospitalized for developing respiratory symptoms, 3 subjects had 5 hospitalizations after treatment, 2 for segmental atelectasis, and 1 of them had bronchoscopy and sputum plug aspiration. Seventeen control subjects were not hospitalized during the treatment period, and hospitalization rates were similar in both groups after treatment. At week 22, BT subjects showed significant improvements in rescue medication use, first second forced expiratory volume (FEV1) as a function of predicted value (prior to relaxant use), and asthma control questionnaire (ACQ) scores compared to controls [(-22.6 ± 40.1) actuations/7 d vs. (-1.5 ± 11.7) actuations/7 d,P<0.05); (14.9±17.4) % to (-0.94±22.3) %,P=0.04; -1.04 ± 1.03 vs. -0.13 ± 1.00,P=0.02], there were still statistically significant differences in rescue medication use and ACQ score compared to the control group at week 52. Although BT is associated with short-term increases in asthma-related symptoms, preliminary confirmation suggests long-term sustained improvement in asthma control.
本期目次

